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The neural crest (NC) is a transient, multipotent cell population present during embryonic 45 
development. The NC can give rise to multiple cell types and is involved in a number of different 46 
diseases. Therefore, the development of new strategies to model NC in vitro enables investigations 47 
into the mechanisms involved in NC development and disease. Here we report a simple and efficient 48 
protocol to differentiate human pluripotent stem cells (HPSC) into NC using a chemically defined 49 
media, with basic fibroblast growth factor (FGF2) and the transforming growth factor-β inhibitor SB-50 
431542. The cell population generated expresses a range of NC markers including P75, TWIST1, SOX10 51 
and TFAP2A. NC purification was achieved in vitro through serial passaging of the population, 52 
recreating the developmental stages of NC differentiation. The generated NC cells are highly 53 
proliferative, capable of differentiating to their derivatives in vitro and engraft in vivo to NC specific 54 
locations. In addition, these cells could be frozen for storage and thawed with no loss of NC properties, 55 
nor the ability to generate cellular derivatives. We assessed the potential of the derived NC population 56 
to model the neurocristopathy, Treacher Collins Syndrome (TCS), by using siRNA knockdown of TCOF1 57 
and by creating different TCOF1+/- HPSC lines via CRISPR/Cas9 technology. The NC cells derived from 58 
TCOF1+/- HPSCs recapitulate the phenotype of the reported Treacher Collins Syndrome murine model. 59 
We also report for the first time an impairment of migration in TCOF1+/- NC and mesenchymal stem 60 
cells. In conclusion, the developed protocol permits the generation of the large number of NC cells 61 
required for developmental studies, disease modeling, and for drug discovery platforms in vitro.  62 
 63 
INTRODUCTION 64 
In mammalian development, neural crest (NC) cells are a transient multipotent population arising from 65 
the neural plate border, usually contemporaneously with neural tube closure [1]. These migratory cells 66 
invade adjacent tissues and differentiate into multiple cell types including mesenchymal stem cells 67 
(MSC), vascular smooth muscle cells (SMC), adipocytes, osteocytes, chondrocytes, melanocytes, glia, 68 
and Schwann cells [2]. NC cells are also implicated in a broad range of pathologies making the in vitro 69 
generation of these cells of high clinical relevance. 70 
The development and function of the NC have been well characterized in animal models including the 71 
chick, zebrafish, and mouse [3-6]. NC specification and induction depends on signaling molecules and 72 
transcription factors, whose actions are coordinated during gastrulation and neurulation. The neural 73 
plate border is specified by the cross talk between BMP, WNT and FGF signaling [7]. Initially, 74 
intermediate levels of BMP signaling induce neural folds with anterior character over the whole neural 75 
plate border. Next, the posterior regions of the neural plate border are transformed into NC under the 76 
effects of FGF, WNT and retinoic acid [8]. After specification, NC cells undergo epithelial-mesenchymal 77 
transition (EMT) before delaminating from the border of the neuroepithelium [9]. Subsequently the 78 
arising NC cells migrate in response to specific cues and express specific proteins including Twist [10], 79 
Sox10 [3,11], and p75 [12]. These factors control cellular events such as delamination, cell 80 
proliferation, migration, and differentiation [13-15]. Defects in the complex processes that 81 
choreograph NC development are involved in congenital human diseases known as neurocristopathies.  82 
 83 
Human embryonic stem cells (HESC) and human induced pluripotent stem cells (HiPSC) are collectively 84 
referred to as human pluripotent stem cells (HPSC). Some of the most relevant NC differentiation 85 
protocols from HPSC are based on initially producing in vitro neuroectoderm [16-18] and then purifying 86 
the nascent NC population using different approaches such as dual SMAD inhibition [18-21] and/or 87 
WNT pathway activation [22-24]. A common limitation of these approaches is the use of undefined 88 
basement membrane extracts as a coating for cell adhesion, while only a few protocols have so far 89 
been validated in vivo [21,24-26]. Further optimization and validation of NC in vitro differentiation 90 
protocols would be valuable for studies into human development and disease. 91 
 92 
Treacher Collins Syndrome (TCS) [27,28] (OMIM: 154500) is a neurocristopathy resulting in a severe 93 
congenital craniofacial disorder which occurs one in every 50,000 births [29]. TCS is primarily 94 
associated with autosomal dominant haploinsufficiency-inducing mutations in the TCOF1 gene located 95 
on chromosome 5 [30], which leads to deficient ribosome biogenesis [31]. Tcof1 is expressed broadly 96 
throughout the mouse embryo, with high activity in the neuroepithelium where it plays an essential 97 
role in cell survival [32]. Extensive apoptosis of the neuroepithelial progenitor has been reported in 98 
TCS, resulting in impaired NC differentiation and subsequent defects in craniofacial development [32].  99 
 100 
In this study, we report a complete differentiation protocol using simple conditions that permits the 101 
generation of the NC from HPSCs using a combination of FGF signaling and TGF-β inhibition. Derived 102 
NC cells are proliferative, can be maintained over multiple passages, can differentiate to a variety of 103 
cell types in vitro and have been validated in a developmental chick embryo model. Furthermore, we 104 
have utilized CRISPR/Cas9 technology to generate TCOF1+/- lines as a model of Treacher Collins 105 
Syndrome, and have revealed abnormalities in cell migration, which may play a role in the underlying 106 
pathology of the disease. The development of this protocol permits the generation of NC and its 107 
derivatives in a chemically-defined media for developmental studies, disease modeling, and drug 108 
discovery.  109 
 110 
MATERIALS AND METHODS 111 
HPSC culture 112 
Human embryonic stem cells (HESC; H9s line, Wicell, Madison,WI) and human induced pluripotent 113 
stem cells (HIPSC; BBHX8 line [33], Cambridge Biomedical Research Centre HIPSC core facility) called 114 
together human pluripotent stem cells (HPSC)  were maintained with chemically defined media (CDM), 115 
plus bovine serum albumin fraction A (CDM-BSA) as previously described [34]. CDM-BSA comprised of 116 
Iscove’s modified Dulbecco’s medium (ThermoFisher Scientific) plus Ham’s F12 NUT-MIX 117 
(ThermoFisher Scientific) medium in a 1:1 ratio,  supplemented with Glutamax-I (ThermoFisher 118 
Scientific), BSA (5mg/ml; Europa Bioproducts),  chemically defined lipid concentrate (ThermoFisher 119 
Scientific), transferrin (15 µg/ml, Roche Diagnostics), insulin (7 µg/ml, Roche Diagnostics) and 120 
monothioglycerol (450μM, Sigma). For the maintenance of HPSCs, CDM-BSA was supplemented with 121 
Activin A (10 ng/ml, R&D Systems) and FGF2 (12 ng/ml, R&D Systems), and cells were maintained on 122 
tissue culture treated plastic coated with 0.1% gelatin (Sigma Aldrich).  123 
HPSC were also cultured and maintained in TeSR™-E8™ media (STEMCELL Technologies) using 124 
Vitronectin XF (STEMCELL Technologies) as chemically defined xeno-free cell culture matrix. 125 
HPSC Differentiation to Neural Crest (NC) 126 
For NC differentiation, HPSC were detached from gelatin-coated plates using 1 mg/ml collagenase IV 127 
(Gibco). Clumps were triturated, counted and plated at a density of 300 colonies/well in 0.1% gelatin-128 
coated 6 well plates in CDM-BSA supplemented with Activin A (10 ng/ml, R&D Systems) and FGF2 (12 129 
ng/ml, R&D Systems), referred to herein as CDM-BSA+FA.  130 
After 24 hours in CDM-BSA, the media was changed to CDM-PVA supplemented with FGF2 (12ng/ml 131 
R&D Systems) and SB-431542 (10μM, Tocris), referred to herein as FSB, for four days without splitting. 132 
CDM-PVA has the same composition as CDM-BSA, with polyvinyl alcohol (PVA, 1 mg/ml, Sigma) instead 133 
of BSA. On day 4 in FSB, the differentiating HPSC were dissociated using TrypLE Express™ (Gibco) and 134 
seeded as single cells at a 1:3 ratio on 0.1% gelatin-coated plates in FSB. The single cells were 135 
maintained in FSB (with daily media changes) on 0.1% gelatin-coated plates over several passages, the 136 
splitting of those single cells was performed every 3-4 days (80-90% confluence) at 1:3 ratio using 137 
TrypLE Express™ (Gibco). 138 
For differentiating HPSC grown on Vitronectin XF and maintained with TeSR™-E8™, the HPSC colonies 139 
were detached using 0.5mM EDTA (Gibco). Clumps were counted and seeded at a density of 300 140 
colonies/well in vitronectin XF-coated 6 well plates in TeSR™-E8™ media. After 24 hours in TeSR™-E8™, 141 
the media was changed to FSB and cells were maintained in FSB on vitronectin XF without splitting for 142 
4-days. At day 4 in FSB, the differentiating HPSC were dissociated with TrypLE Express™, seeded as 143 
single cells on 0.1% gelatin-coated plates and split every 3-4 days as described above. 144 
Quantitative real-time polymerase chain reaction (qRT-PCR) 145 
Total RNA was extracted using the RNeasy mini kit (Qiagen). cDNA was synthesised from 250 ng total 146 
RNA using the Maxima First Strand cDNA Synthesis kit (ThermoFisher Scientific). qRT-PCR reaction 147 
mixtures were prepared with the FAST-SYBR Green Master Mix (ThermoFisher Scientific) and analysed 148 
on a 7500 Fast Real-time PCR system (ThermoFisher Scientific). CT values were normalised to 149 
porphobilinogen deaminase (PBGD). Primer sequences are listed in Supplementary Table 1. 150 
Flow cytometry 151 
Cells were fixed with Cytofix/Cytoperm Fixation solution (BD Biosciences) for 20 min at 4oC, then 152 
washed with Perm Wash Buffer/PBS (1X, BD Biosciences) and permeabilized with Perm Wash 153 
Buffer/PBS + 0.1% Triton-X100 for 30 minutes. Cells were blocked with 3% BSA in 1X Perm Wash Buffer 154 
at room temp for 30 minutes.  After blocking, cells were incubated in primary antibody (Supplementary 155 
Table 2) diluted in 1X Perm Wash Buffer + 0.1% Triton-X100 4oC for 45 minutes. Alexa Fluor®-tagged 156 
secondary antibody was added after primary incubation for 1 hour at room temperature. Samples 157 
were run on a Beckman Coulter CyAn-ADP flow cytometer, and subsequent datasets were analysed 158 
using FlowJo software.   159 
 160 
Immunocytochemistry  161 
Adherent cells were fixed using 4% PFA, permeabilised with 0.5% Triton-X100 in PBS (Sigma) and 162 
blocked with PBS + 3% BSA for 60 minutes at room temperature (RT). Primary antibody (Supplementary 163 
Table 2) incubations were performed at 4oC overnight and Alexa Fluor® tagged secondary antibodies 164 
applied for 45 minutes at RT the following day. Nuclei were counterstained with DAPI (0.1 μg/ml, 165 
Sigma). Images were acquired on a Zeiss LSM 700 confocal microscope and analysed with ImageJ 166 
software. 167 
Western Blotting 168 
Cells were lysed in RIPA buffer containing phosphatase inhibitor cocktail (Sigma) and protease inhibitor 169 
cocktail (Sigma), on ice for 15 minutes and protein content was quantified using a Pierce BCA Protein 170 
Assay Kit (ThermoFisher Scientific). 10μg of protein per sample was resolved by electrophoresis and 171 
transferred to PVDF membranes. Membranes were blocked for 1 hour at room temperature with 5% 172 
milk in Tris-Buffered Saline containing 0.1% Tween-20 (TBS-t, Sigma), and incubated overnight with 173 
either anti-TCOF1 (1:1,000 Abnova), or anti-beta actin (1:10,000 Sigma). Membranes were washed 174 
with TBS-t and incubated with HRP-conjugated secondary antibodies for 1 hour at room temperature. 175 
Membranes were washed and developed using the Pierce ECL2 Western Blotting Substrate 176 
(ThermoFisher Scientific). 177 
Migration assays 178 
Neural crest and mesenchymal stem cells were plated onto six-well plates and allowed to form a 179 
confluent monolayer. The cell monolayer was then scratched in a straight line to make a ‘scratch 180 
wound’ with a 1-ml pipette tip and the cell debris was removed by washing the cells with phosphate-181 
buffered saline. Cells were maintained in FSB (for NC cells) or DMEM + 10% FBS (for MSC), and images 182 
of the closure of the scratch were captured at different time points as indicated. 183 
A chemotaxis assay was performed using the CytoSelect™ 24-Well Cell Migration and Invasion Assay 184 
Combo Kit (Cell Biolabs) following the manufacturer’s instructions. Briefly, 5x105 cells were plated in a 185 
pre-warmed 24-well migration plate in FSB media. The chemo-attractant FGF8B (30 ng/ml, R&D 186 
Biosystems) was added separately to FSB media. Cell media was added to the lower well of the 187 
migration plate. FSB media was used as a control. Cells were incubated for 8 hours at 37 degrees and 188 
quantification was performed following the manufacturer’s instructions. 189 
For single cell analysis of cell migration, cells were imaged real-time on an In-Cell Analyser 2200 (GE 190 
Healthcare Life Sciences) with images collected every 30 minutes for a 12-hour period. Cells were 191 
tracked using the Pointing Cell Tracking plugin for ImageJ (https://imagej.nih.gov/ij/plugins/pointing-192 
cell-tracking/index.html) and migratory profiles were generated using the freely available Chemotaxis 193 
and Migration Tool from Ibidi (ibidi.com/chemotaxis-analysis/171-chemotaxis-and-migration-194 
tool.html). 195 
Microarray Hybridization and Analysis 196 
RNAs isolated from H9s HESC, neuroectoderm [34] and NC passage 2 and 7 (NC P2, NC P7) were 197 
hybridized with Illumina Human HT-12 BeadChip (Illumina Inc., San Diego, http://www.illumina.com). 198 
All the data processing and analysis were performed using the algorithms included with the 199 
Bioconductor package beadarray and Lumi implemented in R software environment for statistical 200 
computing and graphics (R Foundation for Statistical Computing, Vienna, Austria, http://www.r-201 
project.org).  202 
Microinjection of HPSC-derived NC cells and HPSC-derived endoderm cells in chicken embryos 203 
For injections into the cardiac neural crest pre-migratory region, chicken (Gallus domesticus) eggs 204 
(Winter Egg Farm, Cambridge, UK) were incubated in a digital cabinet incubator (OVA Easy 380, 205 
Brinsea) for 32 hours until Hamburger-Hamilton stage 9-10 (HH9-10). Eggs were windowed and 206 
injected under the embryo with India Ink to improve contrast. Small cuts were made with a BD 207 
Microlance needle (size 3) through the vitelline membrane and ectoderm directly adjacent to the 208 
neural tube, at a level just posterior to the forming otic vesicle. Clumps of 50-100 cells in Matrigel were 209 
injected into the cut site used a pulled glass capillary tube. Eggs were re-sealed with tape and cultured 210 
a further 20, 42 and 108 hours after injection to visualise migrating neural crest cells at HH16, HH17, 211 
and  HH26 respectively. HPSC-derived endoderm cells were used as a negative control and generated 212 
as previously reported [35]. 213 
For systemic injections into developing chicken embryo, eggs were incubated until HH24. A small 214 
window was made, and 500-1000 NC cells were administered into the extraembryonic vessels. Either 215 
GFP+ HPSC-derived NC cells or GFP+ HPSC-derived endoderm cells were administered as previously 216 
reported [16] [36]. The window was covered with parafilm (VWR), and eggs were placed horizontally 217 
in the incubator until HH34. Embryos were staining using whole mount immunocytochemistry as 218 
previously described [36].  219 
Differentiation of the NC to various cell types 220 
NC populations were differentiated to smooth muscle cells (SMCs) using a combination of PDGF-BB 221 
(10ng/ml, Peprotech) and TGF-β1 (2ng/ml, Peprotech), as previously reported [37]. NC differentiation 222 
to neuronal populations and mesenchymal stem cells (MSCs) was performed as previously reported 223 
[21]. NC differentiation to melanocytes was performed as previously described [38]. MSC populations 224 
were subsequently differentiated to chondrocytes, adipocytes, and osteocytes using the StemPro 225 
Chondrogenesis Differentiation Kit (ThermoFisher Scientific), StemPro Adipogenesis Differentiation kit 226 
(ThermoFisher Scientific), and StemPro Osteogenesis Differentiation Kit (ThermoFisher Scientific), 227 
respectively, following the manufacturer’s instructions.   228 
Cell Proliferation assay   229 
To assess cell proliferation, the CellTiter 96 Non-Radioactive Cell Proliferation Assay (MTT, Promega) 230 
kit was used, as per the manufacturer’s instructions.   231 
Freezing and thawing of neural crest cells  232 
Confluent NC cells were dissociated with TrypLE Express™ (ThermoFisher Scientific). NC cells were 233 
pelleted and resuspended in CDM-PVA media. 2X106 cells were added to a cryovial using 90% CDM-234 
PVA media with 10% DMSO. NC cryovials were thawed at 37 degrees, and cells transferred to a 15 ml 235 
Falcon tube containing 8 ml of fresh CDM-PVA media. Cells were centrifuged for 3 minutes at 1200 236 
rpm. Cell pellets were resuspended in 1 ml FSB media, and 3 x105 NC cells were plated per well of a 237 
0.1% gelatin-coated well of a 6 well plate. Cells were incubated at 37 degrees overnight in a 5% CO2 238 
incubator. Cell viability was assessed as previously reported [39]. 239 
siRNA knockdown and transient transfections 240 
TCOF1 mRNA was knocked down with siRNA (ThermoFisher Scientific Assay ID S13920). siRNA 241 
transfection (25nM) was performed using DharmaFECT-1 transfection reagent (Dharmacon), following 242 
the manufacturer’s instructions.  243 
Generation of a TCOF1-targeting CRISPR guide RNA/Cas9 Construct 244 
A gRNA targeting the TCOF1 gene was designed to target Exon1 according to the rule of 5’-GN20NGG-245 
3’ (sequence 5’-TGGCTATGTGCGTGCGGCGC-3’). Oligonucleotides were synthesized and ligated into 246 
pSpCas9(BB)-2A-Puro (PX459) V2.0 as previously reported [40]. 247 
Gene Targeting 248 
For gene targeting, 2.5X106 HIPSC were electroporated with one µg of generated TCOF1 targeting Cas9 249 
plasmid in 100ul of nucleofection mix from the P3 Primary Cell 4D-Nucleofector X Kit (Lonza) using a 250 
4D-nucleofector system (Lonza). Transfected cells were plated onto DR4 strain feeders (Jackson 251 
Laboratory) and cultured in advanced DMEM/F12 (Gibco) + 20% KOSR supplemented with FGF2 252 
(4ng/ml) and Rho Kinase inhibitor (Y-27632, 10µM). One day after transfection, cells were selected 253 
with puromycin (1µg/ml, Sigma) for 36 hours. Resistant colonies were picked, expanded, and mutation 254 
introduction was assessed by PCR and Sanger sequencing. 255 
Statistics 256 
One-way ANOVA (Tukey’s multiple comparisons test) and two-sided Student’s t-test were used to 257 
determine statistically significant differences between the groups. Results are presented as mean ± 258 
s.e.m. P values ≤ 0.05 were considered statistically significant. All experiments represent the results of 259 
at least three independent biological replicates (measurements of biologically distinct samples). *P< 260 
0.05; **P < 0.01; ***P < 0.001. 261 
 262 
RESULTS  263 
Dissociation of Differentiating Neuroectoderm During Early Development Promotes NC 264 
Differentiation. 265 
It has been demonstrated that neuroectoderm can be generated from HPSCs utilizing a combination 266 
of FGF2 and the TGF-β inhibitor SB-431542 (referred to herein as FSB) for seven days [16]. Our group 267 
has previously reported the expression of some NC markers during this differentiation process, 268 
including SNAI1, SNAI2, and PAX3, suggesting that a mixed cell population may be generated at these 269 
stages [37]. We hypothesized that cell dissociation with trypsin, a serine protease, might facilitate EMT 270 
and the generation of the NC from this population [41-45]. We, therefore, differentiated the H9s HESC 271 
line to neuroectoderm over seven days with FSB media, with and without WNT3A (25ng/ml, R&D 272 
Systems). At day 7 of differentiation, the neuroectoderm was trypsinized and replated as single cells 273 
in CDM-PVA media supplemented with FGF2 and SB-431542 (FSB) +/- WNT3A for up to 5 passages. 274 
Quantitative RT-PCR over this period showed increased expression of NC differentiation-associated 275 
genes (PAX3, ZIC1, CD49, and SOX9) and the mesenchymal gene (VIM) (Fig.1A). Conversely, 276 
neuroectoderm genes (OLIG3, PAX6) and an epithelial gene (CDH1) were downregulated (Fig.1A), 277 
suggesting that cell dissociation promoted NC marker expression and EMT. Interestingly, the addition 278 
of WNT3A did not have any effect on the expression of these markers during the differentiation 279 
process (Fig.1A).  280 
To further analyze the onset of NC markers during the differentiation of HESC to neuroectoderm over 281 
the first seven days, we assessed the expression of NC (HNK1, P75) and neuroectoderm (PAX6) genes 282 
on a daily basis. We observed the greatest expression of HNK1 and P75 on day 4 of the differentiation 283 
process (Supplementary Fig.1A). Therefore, we hypothesized that dissociation of the developing 284 
neuroectoderm at day 4 instead of day 7, may increase the efficiency of NC generation during the 285 
differentiation process. We analyzed SOX1 and P75 expression by flow cytometry in passaged and non-286 
passaged neuroectoderm at day 4 or day 7 of differentiation in FSB. SOX1 is the earliest known specific 287 
marker of the neuroectoderm lineage and is activated during gastrulation [46]. Neuroectoderm 288 
passaged at day 4 (D4 P1) demonstrated a higher induction of P75 and lower expression of SOX1 when 289 
compared with non-passaged cells or cells split at day 7 (Fig.1B). Furthermore, the cells split at day 4 290 
attached and survived better than the cells split at day 7 (data not shown). Consistent with these 291 
results, TFAP2A, an essential transcription factor for the development of the NC [47,48] was highly 292 
expressed in the D4 P1 population (Fig.1C). SOX1 was detected at the edges of the neuroectoderm at 293 
day 4 and day 7 of differentiation in FSB by immunocytochemistry (Fig.1D). Following passage at day 294 
4, SOX1 expression was significantly reduced. Conversely, SOX1 positive cells remained if passaging 295 
was delayed until day 7 (Fig.1D), suggesting that the greatest reduction of SOX1 was obtained by 296 
passaging the differentiating neuroectoderm in FSB on day 4. Furthermore, HNK1 was highly expressed 297 
in passaged neuroectoderm at day 4 (Fig.1D) and qRT-PCR analyses confirmed these cells showed 298 
significantly higher levels of NC marker TFAP2A and lower levels of neuroectoderm marker GBX2 [49] 299 
than cells from day 7 passaged neuroectoderm (Fig.1E).  300 
Together, these findings suggest that differentiation of neuroectoderm from HPSCS can generate a 301 
mixed population containing both neuroectoderm and NC cells. The NC population can be enriched 302 
from the differentiating neuroectoderm by passaging at day 4 of the protocol.  303 
Serial Passage Increases Purity of NC Cells 304 
Following passaging at day 4, cells were maintained in FSB medium upon reaching confluence (NC P1). 305 
Every four days, the confluent NC cells were split at a 1:3 ratio and seeded for the next passage 306 
(Supplementary Fig.1B). After two passages cells expressed the NC proteins SOX9, HNK1, and P75, and 307 
did not express the neuroectoderm marker SOX1 (Fig.2A). We detected expression of the NC markers 308 
P75 and TFAP2A by flow cytometry following subsequent passaging (Fig.2B and C) [21]. While over 80% 309 
of the early NC population expressed P75, only 50% of the population was double positive for both 310 
P75 and TFAP2A at this stage (Fig.2C). Furthermore, SOX10, a marker of migratory NC, was induced at 311 
D4 of (Fig.2D). These data confirmed that we were generating NC at this time point of the 312 
differentiation process, although the yield was suboptimal.  313 
We questioned whether the differentiated NC would retain their NC-like identity following further 314 
expansion. Interestingly, the expression levels of the NC markers PAX3 and ZIC1, markers of early NC 315 
induction [50,51], peaked at passage 3 (P3). In contrast, SOX9 which is an essential factor for the 316 
further development of migratory NC [52] was observed to be highly expressed at passage 8 (P8) 317 
(Fig.2E top). The expression levels of the neural crest markers P75, TFAP2A, and TWIST1 increased 318 
significantly upon serial passaging (P1, P7, and P13), as assessed by qRT-PCR (Fig.2E bottom), 319 
suggesting that this approach could purify the NC population. 320 
To further confirm the NC cells retain their NC identity and show purification with passaging, we used 321 
flow cytometry to examine the expression of NC and non-NC markers. Furthermore, we repeated the 322 
flow analysis of P75 and TFAP2A in late passages of NC (P12) and observed that 99% of the cells 323 
expressed P75, and 69% showed both P75 and TFAP2A (Fig.2G). Similar results were also obtained 324 
using HIPSC to generate NC cells (Supplementary Fig.2A-C). To assess if the purified NC population 325 
contained additional cell populations, we measured the expression of endoderm (SOX17 and EOMES), 326 
mesoderm, (NKX2.5 and KDR), and neuronal (TUBB3 and MAP2) genes in the populations 327 
(Supplementary Fig.2E). We observed negligible expression of these genes in the NC populations when 328 
compared to HPSC-derived endoderm, mesoderm, or neurons, demonstrating that the NC did not 329 
contain a mixture of these populations in culture. Taken together, these data suggest that NC 330 
purification may be achieved by serial passaging of NC cells in FSB media. Furthermore, we found we 331 
could expand the NC cells up to passage 15 without losing their NC identity [53].  332 
NC Cells are proliferative and Migrate in Response to Specific Chemo-Attractants. 333 
To assess whether passage number or cell density affects the proliferation rate of the differentiated 334 
NC, we performed sequential cell counting and an MTT assay at different NC passages (Supplementary 335 
Fig.2C, D). The MTT Cell Proliferation Assay is used to calculate the cell proliferation rate. The yellow 336 
tetrazolium MTT (3-(4, 5-dimethylthiazolyl-2)-2, 5-diphenyltetrazolium bromide) is reduced by active 337 
cells, to purple formazan that can be solubilized and quantified by spectrophotometric means.  338 
We found that the proliferation rate of NC was independent of passage number (Supplementary 339 
Fig.2C) or cell density (Supplementary Fig.2D). In vivo, NC cells migrate over great distances in response 340 
to chemotactic cues to contribute to tissue development during embryogenesis [54]. To validate a 341 
similar migratory function in our cells, we performed an in vitro scratch assay. NC cells were able to 342 
migrate and cover the scratch within 24 hours (Fig.2F). FGF8 is chemotactic and chemokinetic for NC 343 
in vivo and in vitro [19,54]. We, therefore, examined whether the HESC-derived NC cells would respond 344 
to this cue using the CytoSelect 24-well Cell Migration Assay (8 µm). In response to FGF8B, NC 345 
migration was significantly greater than in FSB media alone (Fig.2H). Overall, these data demonstrate 346 
that the HESC-NC cells recapitulate critical NC functions. 347 
Early Passages of HESC-NC Comprise a Mixed Population of Neural Progenitors and Pre-Migratory 348 
NC Cells that is purified with Serial Passage. 349 
To uncover the differences between early and later passages of NC, we performed a microarray gene 350 
expression analysis using H9s HESC and three independent differentiations of H9s HESC to 351 
neuroectoderm [34], NC at passage 2 (P2) and NC at passage 7 (P7). Hierarchical clustering separated 352 
these populations (Fig.3A). Interestingly, PCA analysis distributed NC P2 in between neuroectoderm 353 
and NC P7 population (Fig.3B). Based on this, we hypothesized that the early NC population could be 354 
a mixture of neuroectoderm and NC cells. 355 
The NC P2 population expressed markers of neural progenitors including AXIN2 [55], FGFR3 [56] and 356 
NOTCH3 [57] (Fig.3C). These genes however, were markedly downregulated at later passages (Fig.3C). 357 
Furthermore, the NC P2 population expressed markers of neural plate border / pre-migratory NC cells 358 
including CDH2 [58], CDH6 [59], FOXD3 [60,61], BMP7, and RHOB [9,62] (Fig.3C). These neural plate 359 
border genes are thought to promote conversion of pre-migratory NC P2 to migratory cells as they also 360 
expressed migratory markers such as B3GAT1 (HNK1) [63,64] in this mixed population (Fig.3C). 361 
As the WNT signaling pathway has been identified as playing important roles in NC development in 362 
vivo [23,65-67], we wondered why exogenous WNT3A was not required in our in vitro differentiation 363 
system. Interestingly, genes related to activation of WNT signaling, such as WNT1, FZD3, DVL2 [68], 364 
and MSX1 [69], were significantly expressed in the early NC P2 population (Fig.3C). These data suggest 365 
there may be endogenous activation of WNT during the early stages of NC differentiation, as observed 366 
in the neural plate border intermediate cells in vivo [69] and in vitro [23]. Interestingly, it has been 367 
proposed that NC induction requires intermediate levels of BMP signaling [70], as part of a BMP 368 
gradient between epidermal ectoderm which expresses both BMP7 and BMP4 [71] and the neural 369 
plate. BMP7 induces the expression of the RHOB protein in the cells destined to become NC in the 370 
neural plate border [9,62]. Consistent with developmental NC induction, BMP7 and RHOB were highly 371 
upregulated in the early NC P2 population compared with NC P7. In contrast, the NC P7 population 372 
expressed higher levels of migratory NC genes such as SOX10, SOX9, TWIST1 and P75 [52,58,72,73] 373 
when compared to the early NC P2 population (Fig.3C).  374 
Finally, we plotted gene expression differences in the NC pathway using an open source pathway 375 
archive (WikiPathway WP2064 revision 47071). Most genes upregulated at NC P2 corresponded to 376 
genes expressed in premigratory NC cells (Fig.3D). This population also showed some migratory NC 377 
genes, suggesting a mixed population. However, genes upregulated in the NC P7 population 378 
corresponded for the most part with genes expressed in the migratory NC (Fig.3D). These data revealed 379 
evidence of endogenous WNT and BMP activity in the NC P2 population. In these early passages, a 380 
mixed NC population could be purified in vitro after several further passages to express a migratory 381 
NC transcriptional profile by passage 7.  382 
HESC-Derived NC Cells Survive, Engraft, Migrate and Differentiate In Vivo at NC Specific Location 383 
Within the Ascending Aorta and the Brain. 384 
NC cells should engraft in the appropriate locations for NC derivatives. In avian embryos, the fate of 385 
the neural crest is well established. The removal of the dorsal neural tube between the otic vesicle and 386 
the third somite in chicken embryos results in a variety of defects of the derivatives of the arch arteries 387 
[74]. Chicken embryos have previously been used as a host for studying the differentiation potential 388 
of human stem cells [36,75,76]. To demonstrate that the NC cells have the potential to migrate and 389 
differentiate to their specific locations in vivo, and that freeze/thaw cycles do not affect the potential 390 
of the NC cells, we performed several experiments engrafting or injecting NC GFP+ cells into chicken 391 
developing embryos.  392 
Fluorescent GFP+ HESC-derived NC P1 cells were thawed, harvested and passed to NC P2 cells. Those 393 
cells were split, counted and embedded into Matrigel for chicken embryo engraftment. Clumps of 50-394 
100 cells were engrafted between the otic vesicle and the third somite, adjacent to the neural tube at 395 
Hamburger and Hamilton (HH) stage 9-10. Some embryos were harvested 20 and 42 hours post 396 
engraftment (HH16-17) to monitor the success of the engraftment. Observation under an inverted 397 
epifluorescent microscope showed they exhibited a lump of GFP+ cells in the region of the otic vesicle. 398 
Furthermore, migrating GFP+ cells were detected in all the embryos (Fig.4A and B). 4.5 days post 399 
engraftment (HH29), whole-mount confocal immunofluorescence imaging of the developing heart and 400 
ascending aorta was performed. A significant number of GFP+ cells were found in the ascending aorta 401 
expressing ACTA2 (Fig.4C). Furthermore, GFP+ cells were not found in the aorta following engraftment 402 
of GFP+ HESC-derived endoderm embedded into Matrigel. Additionally, we could not detect any NC-403 
derived GFP+ cells in the epicardium or myocardium (Fig.4C). Taken together, this data demonstrates 404 
that the engrafted human NC cells can migrate into the ascending aorta and contribute to the SMC 405 
population within the chicken embryo.  406 
We also utilized an alternative method that we have previously validated for using chicken embryos as 407 
a host to study the differentiation and integration of HESC-derived cells [36].  GFP+ NC cells were 408 
injected (500-1000 cells) into the extraembryonic circulation of chicken embryos at HH24. Embryos 409 
were harvested at HH34 and whole-mount confocal immunofluorescence was used for imaging of the 410 
brain, ascending aorta and heart. We detected 10-20 GFP+ NC cells per embryo, around the ascending 411 
aorta (Supplementary Fig.3A-F) and 40-50 GFP+ NC cells per embryo associated with the cerebral 412 
cortex vasculature (Supplementary Fig.3G-J). We could not detect any human NC cells in the 413 
subepicardium either the myocardium (Supplementary Fig.3K), areas we have previously seen the 414 
localization of HESC-derived epicardial cells [36]. HESC-derived NC cells could be clearly discriminated 415 
from the host cells by their cell size, high green fluorescence (Supplementary Fig.3A, D, G) and distinct 416 
nuclei (Supplementary Fig.3B, E, H). Some of the engrafted NC cells around the ascending aorta also 417 
expressed ACTA2, suggesting the onset of EMT and SMC differentiation in situ within the ascending 418 
aorta (Supplementary Fig.3C). Together, these results suggest that HESC-derived NC cells have access 419 
to ascending aorta in vivo and have the potential to contribute to tissue development in this location. 420 
In Vitro Differentiation of NC to a Variety of Cell Types  421 
NC cells can differentiate in vivo into a wide range of cell types such as neurons, melanocytes [77-79] 422 
mesenchymal stem cells (MSC) [80], adipocytes [81], chondrocytes, osteocytes [82,83] and vascular 423 
SMC [84]. We, therefore, followed a wide range of established differentiation protocols to confirm that 424 
our purified NC cells (NC P7 and further passages) were able to differentiate into their known 425 
derivatives. 426 
To assess the capability of the NC to differentiate into neurons, we plated cells on polyornithine-427 
laminin-coated culture dishes [21]. After ten days of differentiation, these cells spontaneously 428 
differentiated into beta III Tubulin+ neurons (Fig.5A). Neuronal morphology was confirmed by 429 
microscopy (Supplementary Fig.4B). Differentiation to SMC from NC was performed following our 430 
previous protocol [34]. SMC proteins such as ACTA2, SM22A, and CNN1 were detected by 431 
immunocytochemistry at twelve days of differentiation (Fig.5B). ACTA2, TAGLN and other SMC 432 
markers such as MYH11, SMTN-B and MYOCD were also upregulated in differentiated SMC as assessed 433 
by qRT-PCR (Supplementary Fig.4H).  434 
Melanocyte differentiation was achieved following a previously reported protocol [38]. qRT-PCR 435 
assessed differentiation for melanocyte markers KIT and MITF [38] and NC markers such as P75 and 436 
FOXD3 (Fig.5C). NC-derived melanocytes showed statistically significant upregulation of KIT and MITF 437 
expression and a marked downregulation of P75 and FOXD3. Typical melanocyte morphology was 438 
confirmed by microscopy (Supplementary Fig.4C). Mesenchymal stem cells (MSC) were derived from 439 
the NC using a previously reported protocol [21]. Differentiated MSC were positive for CD44 and 440 
negative for P75 as assessed by flow cytometry (Fig.5D), and expressed the MSC marker CD105 (ENG) 441 
by qRT-PCR (Supplementary Fig.4D) [85]. Chondrocytes, adipocytes, and osteocytes were successfully 442 
differentiated from NC using specific commercial differentiation media, following the manufacturer’s 443 
instructions (ThermoFisher Scientific). Chondrocyte differentiation was demonstrated by Alcian Blue-444 
positive staining of NC-derived chondrocytes (Fig.5E). ACAN expression [86] also confirmed 445 
chondrocyte lineage (Supplementary Fig.4E). Adipocyte differentiation was determined by positive oil 446 
red O staining (Fig.5F) and PPARG [87] expression (Supplementary Fig.4F). Osteocyte differentiation 447 
was shown by positive alizarin red staining (Fig.5G). COL1A1 [88] and Osteocalcin [89] were detected 448 
by immunocytochemistry in osteocytes derived from NC (Supplementary Fig.4G, top panel). 449 
Furthermore, the expression levels of the osteocyte genes sclerostin (SOST) and COL1A1 were 450 
measured by qRT-PCR, revealing robust upregulation in NC-derived osteocytes (Supplementary Fig.4G, 451 
bottom panel). 452 
Finally, we examined the ability of these cells to function as NC cells after freeze-thawing. NC cells were 453 
frozen at passage 7 then defrosted and cultured for 2 further passages and retained their NC marker 454 
expression comparable to passage 9 NC cells that had not undergone freeze-thawing (Supplementary 455 
Fig.4I, top panel). Similarly, freeze-thawing had no effect on the ability of the NC cells to generate 456 
derivatives such as smooth muscle cells (Supplementary Fig.4I, bottom panel). Furthermore, viability 457 
assays performed in thawed NC P2 and NC P7 cells [39] shown a recovery of 89±6.5% and 92.5± 6.25 458 
% respectively from frozen vials (Supplementary Fig.4J). The ability to freeze and store these cells is 459 
important for the practical utilization of these cells, which can now be bulked up for storage and use 460 
as required, without losing NC properties. 461 
Down-Regulation of Treacle Expression by siRNA impairs cell migration in NC and MSC.  462 
Haploinsufficiency of TCOF1 in humans is associated with TCS; a condition characterized by craniofacial 463 
abnormalities thought to be due to impaired NC development [90]. To determine whether TCOF1 464 
haploinsufficiency results in NC defects in humans, we initially investigated its role in HPSC-derived NC 465 
by siRNA-mediated knockdown. Transfection of TCOF1-targeted siRNA reduced mRNA expression in 466 
both NC and MSC as assessed by qRT-PCR (Supplementary Fig.5A), and at the protein level in the NC 467 
by flow cytometry (Supplementary Fig.5B). To investigate whether TCOF1 has any role in the 468 
differentiation of NC to MSC, we differentiated NC P7 cells transfected with siRNA against TCOF1 or 469 
Scramble siRNA to a MSC fate as previously reported [21]. We observed no difference in the capacity 470 
for MSC differentiation from TCOF1 knockdown NC with upregulation of CD44 and downregulation of 471 
P75 observed in both knock-down and control conditions (Fig.6A).  472 
In mice, Treacle plays a role in NC development and proliferation [32]. We assessed if siRNA-mediated 473 
knockdown of TCOF1 impaired proliferation of HPSC-derived NC by performing an MTT assay. As in the 474 
mouse, we observed decreased proliferation in siRNA-mediated TCOF1 knockdown cells when 475 
compared controls (Fig.6B). It has previously been suggested that migration is not impaired in Tcof1+/- 476 
mice [32]. To assess the role played by TCOF1 in human NC, we performed a wound healing scratch 477 
assay following siRNA-mediated knockdown of TCOF1. We observed impaired migration and scratch 478 
closure in TCOF1 knockdown NC when compared to controls (Fig.6C). Furthermore, whilst the 479 
migratory defect in this assay could be attributed to the documented impaired proliferation (Fig.6B), 480 
the migration phenotype was detected as early as 6 hours post-scratch, suggesting that the phenotype 481 
was indeed due to impaired migration. We performed further validation of this migratory defect using 482 
a Cytoselect™ transwell cell migration assay (Fig.6D). siRNA-mediated knockdown of TCOF1 produced 483 
a significant reduction in NC migration compared with controls (Fig.6D). This migration impairment 484 
was observed in FSB medium alone and observed in response to different NC chemo-attractors such 485 
as FGF8B [19] or 10% fetal bovine serum (Fig.6D). NC-derived MSC transfected with siRNA against 486 
TCOF1 also showed a similar migratory defect in a wound healing scratch assay (Fig.6E). Taken 487 
together, these findings demonstrate that TCOF1 may play a role in both the proliferation and 488 
migration of the human NC. 489 
Modeling TCS in Vitro with TCOF1+/- HIPSC using CRISPR/CAS9 technology. 490 
To further confirm the results observed using TCOF1 siRNA in our NC model and to try to model TCS in 491 
vitro, we created heterozygous TCOF1+/- KO HIPSC lines using CRISPR/Cas9 technology to accurately 492 
target Exon 1 of the TCOF1 gene in wild-type HIPSC (Fig.7A). Cas9-induced double-strand breaks in 493 
TCOF1 genomic DNA were repaired by the non-homologous end joining pathway leading to insertions 494 
or deletions (INDEL) in different HIPSC clones (Fig.7B). HIPSC Clones 12 and 24 (C12 and C24) had the 495 
same single nucleotide deletion in Exon 1 as observed by Sanger sequencing. This removal created a 496 
premature stop codon, resulting in a heterozygous KO for TCOF1 (Fig.7B). HIPSC Clone 8 (C8) was also 497 
transfected, but no INDELs were detected in the TCOF1 gene (data not shown). We, therefore, used 498 
C8 as an isogenic wild-type HIPSC line to compare with the TCOF1+/- clones (C12 and C24). NC was 499 
generated from all three clones, and NC P7 cells were used for subsequent studies. Immunoblotting 500 
for Treacle confirmed a significant reduction of protein levels in NC derived from TCOF1+/- HIPSC clones 501 
(C12 and C24) compared with isogenic wild-type clone 8 NC and wild-type HESC-derived NC (Fig.7C).  502 
The downstream effect of defective ribosomal biosynthesis in mutant Tcof1+/- mice is a lower 503 
proliferative index than wild-type NC cells [32]. TCOF1+/- NC derived from clones C12 and C24 had 504 
significantly lower proliferation rate than similar wild-type NC cells derived from the C8 line and WT 505 
HESC, validating the findings observed in the Tcof1+/- mouse (Fig.7D). 506 
The underlying cause of the reported craniofacial anomalies in the Tcof1 +/- mice is increased apoptosis 507 
in the neuroepithelium [32]. This developmental stage overlaps with the period of NC induction and 508 
migration from the neural plate border during embryogenesis [27]. To investigate whether our in vitro 509 
TCS model recapitulated this phenotype, we differentiated WT and TCOF1+/- HIPSC lines to 510 
neuroectoderm [34]. Flow cytometric analyses for Annexin V confirmed a marked induction of 511 
apoptosis in neuroectoderm cells derived from TCOF1+/- HIPSC (C12 and C24) compared with 512 
neuroectoderm derived from WT HIPSC Clone 8 or parental WT HESC (Fig.7E).  513 
As we unveiled a previously unreported migratory defect in NC and NC-derived MSC deficient for 514 
TCOF1 by siRNA (Fig.6C and 6E), we performed the same analysis on the generated TCOF1+/- lines. A 515 
wound healing scratch assay demonstrated impaired migration in both NC (Supplementary Fig.6A), 516 
and MSC (Supplementary Fig.6B) derived from TCOF1+/- HIPSC C24. To further investigate this 517 
migratory defect uncovered by the wound healing scratch assay, we performed single cell analysis of 518 
cell migration and directionality of movement using real-time imaging of cells over a 12-hour time 519 
course. This analysis demonstrated that whilst WT HIPSC Clone 8 derived NC cells migrated freely in 520 
multiple directions over a 12-hour period, TCOF1+/- HIPSC derived NC cell show considerable 521 
impairment of migration at a single cell level (Fig.7F).  These findings further validate the reduced 522 
migration phenotype of TCOF1-deficient NC cells in the human context.  523 
 524 
DISCUSSION 525 
This study first describes a simple and efficient method of generating NC cells from HPSC using 526 
chemically defined media.  Importantly, this in vitro system has great potential for investigating the 527 
molecular and cellular defects in neurocristopathies such as TCS. We have established a model of 528 
Treacher Collins Syndrome using CRISPR/Cas9 gene editing and identified novel NC and MSC migration 529 
defects in our in vitro model.  530 
Development of a Differentiation Protocol to Generate NC from HPSCs using a Chemically Defined 531 
Media  532 
Several methods have been reported to produce NC from HPSCs, although further work is required to 533 
allow the production of cells in a fully chemically defined media and to reduce the complexity of the 534 
differentiation conditions. The limitations of the previously reported protocols include the use of 535 
biological substrates such as Geltrex™ [21] or Matrigel™ [23] that display original batch to batch 536 
variability. Other protocols used media enriched with complex Supplements such as N2™ and B27™ 537 
[23,43].  538 
We have demonstrated that we can generate NC cells from HPSC using minimal cytokines when 539 
compared with previous protocols [18-21] or WNT pathway activation [23]. This reduction of cytokines 540 
makes our protocol simpler and more economically viable. Furthermore, we do not need to perform 541 
cell sorting to generate our populations, as we have observed that serial passaging effectively purifies 542 
the populations generated. We have also demonstrated that our cells can undergo freeze-thawing with 543 
up to 90% recovery rates and viability, permitting these cells to be used to generate stocks of NC cells 544 
at the same passages (Supplementary Fig.4J). We have used thawed NC cells for multiple 545 
differentiations and have not seen any alterations in their maintenance or differentiation capacity 546 
following thawing.  Therefore, our protocol permits the generation of a high number of NC cells which 547 
can be banked and used at later dates.  548 
The differentiation of NC from HPSCs using this approach recapitulates, to some extent, the normal 549 
embryonic developmental stages. In our protocol, the passage of neuroepithelial neuroectoderm at 550 
low density in FSB appeared to select the NC population in vitro. The genome-wide mRNA expression 551 
studies suggested that earlier passages of NC populations were a mixed population of neural 552 
progenitor cells and premigratory NC cells.  Premigratory NC genes such as RHOB, CDH6, FOXD3 and 553 
neural progenitor genes such as AXIN2 [55], LHX2 [91], DVL2 [92] and OLIG2 [93], were upregulated in 554 
these populations (Fig.3B). It has been previously reported that the patterning of neural versus NC 555 
lineages is based on the plating density of early progenitors [18]. Serial passage of our cells at low 556 
density, selected against the neural population, with a significant downregulation of neural genes by 557 
later passages (P7). Meanwhile, the P7 cells expressed markers of migratory NC cells, including SOX9, 558 
SOX10, P75, and TWIST, and downregulated pre-migratory markers such as WNT1, PAX3, and RHOB. 559 
Further validation of in vitro selection upon serial passaging is provided by the pattern of expression 560 
of SOX10 and WNT1. In the mouse, Sox10 expression follows Wnt1 expression and marks virtually all 561 
NC cells immediately after their delamination from the neural tube [94]. In our system, WNT1 is lowly 562 
expressed in mixed NC population, while it increases alongside SOX10 expression in further passages, 563 
confirming NC purification in vitro with passaging. 564 
In contrast to other in vitro protocols [18,19,21,43] we did not need to modulate WNT or BMP signaling 565 
exogenously. We hypothesized that the endogenous activation of WNT and BMP signaling, as 566 
evidenced by our microarray analysis, was sufficient in early passages to induce NC differentiation. This 567 
endogenous signaling may reflect the cross-talk and local gradients between a mixed population of the 568 
neural plate and non-neural plate ectoderm. Upon further passage of the mixed NC P2 population, we 569 
observed downregulation of both BMP and WNT signaling cells in these populations, suggesting that 570 
the combination of endogenous BMP and WNT signaling at the early stages of the differentiation 571 
protocol was sufficient to specify NC differentiation. The protocol imitates, in part, the steps involved 572 
in the development of NC cells in the embryo [9]. 573 
The properties of NC cells generated with this protocol were broadly characterized both in vitro and in 574 
vivo. We demonstrated the expression of NC markers from passage 7 to beyond. NC cells could 575 
proliferate, self-renew and migrate to appropriate cues such as FGF8B has previously been reported 576 
[54]. Furthermore, we successfully demonstrated that these NC cells differentiate into their derivatives 577 
lineages including MSC, melanocytes, peripheral neurons, smooth muscle cells, adipocytes, 578 
chondrocytes, and osteocytes (Supplementary Fig.4) [21,23,95].  579 
Importantly, in vivo characterization provides a critical test of a progenitor population’s developmental 580 
capacity. To determine whether HPSC derived NC cells demonstrated functionality in vivo, we 581 
evaluated the integration and migration of these cells in the developing chick embryo. We found the 582 
engrafted NC cells localized in the wall of the ascending aorta (Fig.4), the aortic arch and the meningeal 583 
vessels of the brain (Supplementary Fig.3). The absence of NC cells in the epicardium and sub-584 
epicardial regions of the heart confirmed the specificity of these cells in localizing correctly to NC in 585 
vivo developmental location. There could be several factors that mediate the migration and 586 
localization of human NC cells in vivo including paracrine signals from chicken NC-derived tissues or 587 
cell-cell and cell-matrix interactions at particular NC-derived locations. Whilst we have demonstrated 588 
that our HIPSC-derived NC can contribute to the aortic SMC population in vivo, we have not explored 589 
the broad differentiation of these cells using this approach. The ability to transplant HIPSC-derived 590 
cells in ovo provides an opportunity to further our understanding of the developmental potential of 591 
human progenitor cells within an in vivo context. Analysis of NC, neuron/glial and pericyte marker 592 
expression in the transplanted cells may provide additional insight into the differentiation potential of 593 
these cells in vivo and their cell fate.  594 
Modeling Treacher Collins Syndrome In Vitro 595 
The ability to generate NC from patient-derived HIPSC lines provides a unique tool to study 596 
neurocristopathies in the affected cell lineage. A complementary approach to study specific diseases 597 
is the de novo creation of a particular mutation in wild-type lines of HPSC using CRISPR/Cas9 gene 598 
editing. This method permits the investigation of multiple diseases causing mutations, without the 599 
requirement of patient tissue. Moreover, this approach removes the influence played by various 600 
genetic backgrounds from different patient samples.  601 
A vast number of NC-related diseases have been reported in the literature, including TCS, although 602 
studies using human models are lacking. Treacle protein depletion has been attempted previously 603 
using knock-in of a destabilization domain-tagging TCOF1 in HEK293 cells, resulting in impaired cell 604 
proliferation [87]. Furthermore, mice haploinsufficient for Treacle have been reported and 605 
demonstrate robust developmental NC phenotypes [32].  606 
To finally confirm the quality and utility of the HPSC-derived NC using this protocol we attempted to 607 
model Treacher Collins Syndrome in vitro. We created TCOF1+/- HIPSC lines from wild-type cells using 608 
CRISPR/Cas9 technology. The differentiation of TCOF1+/- HIPSC clones with our protocol provided the 609 
opportunity to study the functionality of the affected NC cells. TCOF1+/- HIPSC derived NC cells 610 
displayed significant depletion of Treacle protein and their phenotype corresponded to the mutant 611 
phenotype found in the Tcof1 +/- mouse model [32].  612 
Furthermore, neuroectoderm derived from TCOF1+/- HIPSC showed a dramatic increase in apoptosis, 613 
replicating the aberrant cell death in the neural plate in Tcof1 +/- mice [32]. The haploinsufficiency of 614 
Treacle also leads to reduced proliferation of NC cells in Tcof1 +/- mice [32]. NC derived from TCOF1+/- 615 
HIPSC also showed a significant reduction in proliferation compared with wild-type HIPSC-derived NC 616 
cells. Strikingly, we also demonstrated a previously unappreciated impairment in the migration of both 617 
TCOF1+/- NC and NC-derived MSC in our in vitro model. Models of Treacher Collins syndrome have been 618 
reported in both the zebrafish and the mouse [32,96]. Both systems demonstrate extensive 619 
craniofacial abnormalities, yet the developing NC populations are shown to migrate and populate the 620 
maxillary and frontonasal regions normally. It is of interest to note that whilst there is no reported 621 
difference in the migration behavior of the NC, there is an overall reduction in the number of migrating 622 
NC cells, and this has been demonstrated to be due to a proliferation and cell death defect at the early 623 
stages of NC delamination from the neuroepithelium. However, it is possible that the finding of fewer 624 
migrating NC cells in this model may also be due to a proportion of cells which fail to migrate, in 625 
addition to the clear cell survival defects reported [32,97]. Whilst we report a migration defect in our 626 
TCOF1+/- HIPSC-based NC system, it is important to acknowledge that this is an in vitro model and so is 627 
limited by the many missing developmental cues and triggers which are present in vivo. Therefore, it 628 
is possible that the migratory phenotype we report here may not be recapitulated during human in 629 
vivo development. Further engraftment studies using TCOF1+/- HIPSC-derived NC within the cranial NC 630 
may provide novel insights into the mechanisms involved during the migration of the human NC and 631 
their contribution to cells of the facial prominences and subsequent craniofacial compartments. 632 
Nevertheless, our TCOF1+/- HIPSC-based NC model now adds to the limited information available 633 
regarding human NC development and its contribution to Treacher Collins syndrome. 634 
CONCLUSION 635 
We believe that this protocol will serve as a resource for researchers seeking to produce NC and NC-636 
derived tissues and to model neurocristopathies in vitro. Furthermore, we have shown that NC cells 637 
derived from HPSCs can be differentiated into a wide variety of cell lineages which is of great interest 638 
to the field. The ability to study the mechanisms of NC biology and disease should also accelerate the 639 
development of innovative therapies to treat, or even prevent, NC disorders such as TCS.  640 
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